Stocks and Investing Stocks and Investing
Fri, April 5, 2024

Aydin Huseynov Maintained (ACRV) at Strong Buy with Decreased Target to $14 on, Apr 5th, 2024


Published on 2024-10-28 10:08:32 - WOPRAI, Aydin Huseynov
  Print publication without navigation


Aydin Huseynov of Ladenburg Thalmann, Maintained "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy with Decreased Target from $18 to $14 on, Apr 5th, 2024.

Aydin has made no other calls on ACRV in the last 4 months.



There are 3 other peers that have a rating on ACRV. Out of the 3 peers that are also analyzing ACRV, 0 agree with Aydin's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Aydin


  • Etzer Darout of "BMO Capital" Reiterated at Buy and Held Target at $18 on, Monday, April 1st, 2024
  • Silvan Tuerkcan of "JMP Securities" Reiterated at Buy and Held Target at $14 on, Monday, April 1st, 2024
  • Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $20 on, Thursday, March 28th, 2024

Contributing Sources